RxDoctor Payments Data

Eddy Bruno, MD

Psychiatry · Lima, OHNPI 1427080530

Payments from drug & device makers

$4,328in general payments, 2019–2025

Across 329 payments — averaging $13.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$458
  • Alkermes, Inc.$455
  • Sunovion Pharmaceuticals Inc.$295
  • Teva Pharmaceuticals USA, Inc.$218
  • Otsuka America Pharmaceutical, Inc.$154
  • plus $464 from 5 others

What the payments were for

  • Food & beverage$4,13796%
  • Education$1914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,328 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$63,504
Medicare patients
186
Services billed
949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate149$505,181
VraylarCariprazine Hcl113$167,361
IngrezzaValbenazine Tosylate16$127,133
TrintellixVortioxetine Hydrobromide84$58,164
Aripiprazole276$50,277
Lurasidone Hcl52$48,128
RexultiBrexpiprazole24$35,583
CaplytaLumateperone Tosylate13$23,825
LybalviOlanzapine/Samidorphan Malate13$21,234
Clozapine131$18,170
Vilazodone Hcl162$15,535
BelsomraSuvorexant34$15,529
Quetiapine Fumarate ErQuetiapine Fumarate128$12,977
Ziprasidone Hcl83$9,108
SavellaMilnacipran Hcl12$8,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$76$505,181149 claims
AbbVieVraylar, Savella$2,285$176,261125 claims
Neurocrine Biosciences, Inc.Ingrezza$458$127,13316 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$48$58,16484 claims
Otsuka America Pharmaceutical, Inc.Rexulti$154$35,58324 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$115$23,82513 claims
Alkermes, Inc.Lybalvi$455$21,23413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →